Altar M. Munis
PhD, BSc (Hons)
Postdoctoral Research Scientist
Funded by the Wellcome Trust, I am working on the development and optimisation of lentiviral gene therapy for lung diseases. In particular, my current project focuses on the treatment of surfactant protein B deficiency, a fatal autosomal recessive genetic disorder, using Sendai virus F/HN pseudotyped vectors.
Prior to joining the Gene Medicine group, I undertook my doctoral studies in gene therapy and immunology at University College London investigating the properties of phylogenetically distinct vesiculovirus glycoproteins that may have advantages over the prototypical glycoprotein from VSV Indiana strain.
A human surfactant B deficiency air-liquid interface cell culture model suitable for gene therapy applications
Munis AM. et al, (2021), Molecular Therapy - Methods and Clinical Development, 20, 237 - 246
Genome-wide Integration Site Detection Using Cas9 Enriched Amplification-free Long-range Sequencing
HYDE S. et al, (2020), Nucleic Acids Research
A tool with many applications: vesicular stomatitis virus in research and medicine.
Munis AM. et al, (2020), Expert Opin Biol Ther, 20, 1187 - 1201
Gene Therapy Applications of Non-Human Lentiviral Vectors.
Munis AM., (2020), Viruses, 12
Use of Heterologous Vesiculovirus G Proteins Circumvents the Humoral Anti-envelope Immunity in Lentivector-Based In Vivo Gene Delivery
Munis AM. et al, (2019), Molecular Therapy - Nucleic Acids, 17, 126 - 137